Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pyrotinib + pertuzumab + trastuzumab
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy consists of pyrotinib, an irreversible pan-ErbB tyrosine kinase inhibitor, alongside the monoclonal antibodies pertuzumab and trastuzumab. It is being evaluated as a precision treatment for HER2-positive salivary gland carcinoma in a Phase 2 umbrella trial sponsored by Peking Union Medical College. Pyrotinib inhibits the intracellular kinase domains of HER1 (EGFR), HER2, and HER4, while trastuzumab and pertuzumab bind to distinct epitopes on the extracellular domain of the HER2 receptor to inhibit dimerization and downstream signaling. This multi-pronged approach aims to achieve more complete blockade of the HER2 pathway to overcome resistance and improve efficacy in HER2-driven malignancies.
- Brand names
- AiRuiNi
- Other names
- pyrotinib + pertuzumab + trastuzumab-Peking Union Medical College-salivary gland carcinomaHER2-targeted triple therapyHER-2-targeted triple therapyHER 2-targeted triple therapy
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)
Beyond the preview
Go deeper on pyrotinib + pertuzumab + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pyrotinib + pertuzumab + trastuzumab.